BIT225 is in mid‑stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 has been dosed in 55 healthy human volunteers and 94 subjects infected with either HIV-1, HCV or co-infected with HIV-1/HCV. Clinical trial results for BIT225 include: HIV-1 BIT225 is a novel first-in-class HIV-1 … Continue reading Clinical programs